Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q3 2024 · 10-Q
Revenue$411.00K$411.00K+128.3% vs Q3 2023 Net Income-$6.35M-$6.35MN/M vs Q3 2023 EPS Diluted-$0.22-$0.22no prior Q3 2023 on file Operating Income-$7,884,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-1918.2%+3507.6 pt vs Q3 2023
Net margin-1545.0%+3877.9 pt vs Q3 2023
ended Dec 31, 2023 · filed Feb 13, 2024 · 44 d after period end